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AbstractW
fntroductionW
Cardiovascular  diseases  ECsaF are  becoming  more  prevalent  in  efsJinfected  populations  as  they  age  largely  due  to  improved
treatment outcomes. Assessment of Csa risk and Csa risk factors in efsJpositive populations has focused on high income settingsI
while there are limited studies evaluating Csa in efsJpositive populations in the Asian region.
Materials and MethodsW
te provided an overview of the prevalence and incidence of Csa and its risk factors in adult efsJpositive populationsI and of the
strategies currently in place for Csa management in the Asian region.
oesultsW
ptudies from the Asian region showed that Csa and Csa risk factorsI such as dyslipidaemiaI elevated blood glucoseI obesity and
smokingI are highly prevalent in efsJpositive populations. A number of studies suggested that efs infection and antiretroviral
therapy may contribute to increased Csa risk.  kational  efs treatment guidelines provide some directions regarding Csa risk
prevention and management in the efsJinfected populationI howeverI they are limited in number and scope.
ConclusionW
aevelopment and consolidation of guidelines for integrated Csa and efs care are essential to control the burden of Csa in efsJ
positive populations. To inform guidelinesI policies and practice in the Asian regionI research should focus on exploring appropriate
Csa risk screening strategies and estimating current and future Csa mortality and morbidity rates.
* Address correspondence to this author at the The hirby fnstituteI rkptI pydneyI tallace turth BuildingI rkpt pydney kpt 2MR2I Australia;
TelW HSN29P8RM9MM; caxW HSN29P8RM92M; bJmailW rbijker@kirby.unsw.edu.au
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heywordsW efsI Cardiovascular diseaseI Cardiovascular risk factorsI Asia.
N. fkTolarCTflk
aue to largely improved antiretroviral therapy EAoTF outcomesI efs positive individuals are growing older and as
a result  chronic diseases associated with agingI including cardiovascular diseases ECsaF and cancerI  are becoming
more prevalent in the efsJinfected population xN]. A recent review of data from high income countries estimated that
efs populations have around a twofold increased risk of experiencing Csa events compared to the general population
x2].
pimilar  to  risk  factors  in  the  general  populationI  Csa  in  the  efsJinfected  population  can  be  caused  by  nonJ
modifiable risk factors including older age and family history of CsaI and modifiable risk factors such as medical
conditions Ee.g. hypertensionI diabetesI dyslipidaemiaF and behavioural factors Ee.g. smoking and dietF. curthermoreI the
increased  risk  of  Csa  might  also  be  attributable  to  risk  factors  specific  to  the  efsJpositive  populationI  such  as
compromised immunity xPI 4]I immune activationI efs associated inflammation xR]I and receiving AoT xSI T].
Assessment of Csa risk and Csa risk factors in efs populations has focused on high income settingsI while there
are limited studies evaluating Csa in efs populations in the Asian regionI where income levels greatly differ across
countries x8]. This review aims to provide insight on the prevalence and incidence of Csa and its risk factors in adult
efs populations in the Asian region.
te defined Csa as strokeI myocardial infarction and coronary heart disease ECeaF and we considered blood lipid
levelsI diabetes and blood glucose levelsI abdominal obesityI hypertension and smoking as Csa risk factors. te report
research findings from the last NM years of studies conducted in ChinaI fndiaI fndonesiaI gapanI MalaysiaI pouth horeaI
TaiwanI ThailandI CambodiaI MyanmarI the mhilippines and sietnam.
then requiredI differences were reported between efs negativeI AoT naïveI and AoT experienced populations. fn
additionI we provide an overview of the strategies currently in place for Csa management in efsJpopulations in the
Asian region. te conclude with future directions for practice and research.
2. CAoaflsApCriAo afpbApb Aka CAoafAC crkCTflkfkd
cew studies have evaluated cardiovascular health in efsJpositive populations in the Asian region. Table N provides
an  overview  of  studies  evaluating  Csa  events  and  surrogate  markers  of  cardiovascular  dysfunction.  lne  recent
Taiwanese study assessed the incidence of stroke in patients with efs compared with nonJinfected individuals from the
Taiwan kational eealth fnsurance oesearch aatabase x9]. The study showed that stroke occurred more frequently in
those with efs EM.9S% vs. M.24%F.
fn factI independent of other traditional Csa risk factorsI efs infection was associated with a 2.TR fold increased
risk E9R% Confidence fnterval xCf] N.NTJS.44F of having a stroke x9]. curther evidence of Csa risk stems from studies
investigating surrogate measures of CsaI such as carotid artery plaque and carotid intimaJmedia thickness. A study
from pouth horea found that 2P.4% of efs patients receiving AoT had carotid artery plaque and that AoT use was
significantly  associated  with  the  existence  of  carotid  artery  plaque  xNM].  fn  a  small  fndian  study  populationI  no
significant difference was found in carotid intimaJmedia thickness between AoT experienced and AoT naïve patients
xNN].
peveral studies in the Asian region have used twoJdimensional echocardiogram to assess cardiac function in efsJ
positive populations. fn fndiaI echocardiographic abnormalities were identified in ST.M% of efsJinfected patients xN2].
aiastolic  dysfunction  EaaF  was  the  most  common  abnormality  occurring  in  48.2%  of  patientsI  followed  by  left
ventricular systolic dysfunction occurring in NT.S% of patients.
pimilar proportions of aa were found in Chinese patients on AoTI which was substantially lower compared to
proportions of aa E2M%F detected in efs negative individuals xNP]. A Chinese longitudinal study found that cardiac
abnormalitiesI including left ventricular systolic dysfunctionI aaI increased left ventricular mass index and pulmonary
arterial hypertensionI were more prevalent 48 weeks after AoT initiationI although this finding was only significant for
aa xN4]. This study also showed efs infection to be independently associated with aa and increased left ventricular
mass index.
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Table N. pummary of studies assessing the prevalence or incidence of CsaI cardiac abnormalities and Csa risk.
ptudy ErefsF CountryI income
group
ptudy design mopulation
k E% maleFI mean age
EpaF
lutcome cindings
TohI 2MN4 x9] TaiwanI
high income
CrossJsectional S22 efsH and N244 efsJ
Eunsp.F P4.R years
ptroke fncidence of stroke in efsH vs.
efsJ
JM.9S% vs. M.24% Ep=M.MST8F
aifferences between efsH and
efsJThose with efs more
frequently had stroke Elo 2.TRI
9R% Cf N.NTJS.44I p=M.MN99F #
geongI 2MNP xNM] pouth horeaI
high income
CrossJsectional N4R efsH E9S%F 4M.9
years ENM.8F
purrogate Csa
measure
mrevalence of carotid artery
plaque
J2P.4%
aifferences between on AoT
and AoT naïve
JThose on AoT more frequently
had carotid artery plaque
Ep<M.MRF #
puparnaI 2MNP xNN] fndiaI
lowerJmiddle
income
CrossJsectional 42 efsH EST%FW 2S on
AoTI 28.S years ET.MF; and
NS AoT naïveI P4.N years
ES.9F
purrogate Csa
measure
aifferences between on AoT
and AoT naïve
Jko significant difference in
carotid intima media thickness
Ep=M.4SF
gainI 2MN4 xN2] fndiaI
lowerJmiddle
income
CrossJsectional NMM efsH ET8%FI PT.P
years E8.TF ^
Cardiac
abnormalities
mrevalence of cardiac
abnormalities¥
JCumulative cardiac
abnormalitiesW ST.M%
JaaW 42.8%±
Jieft ventricular systolic
dysfunctionW NT.S%°
iuoI 2MNM xNP] ChinaI
upperJmiddle
income
CrossJsectional 42 Afap ESM%FI 4M.S years
E9.PF; 42 efsH ESM%FI
P8.S years ES.RF; PM efsJ
ESM%FI 4N.R years ENM.RF
Cardiac
abnormalities
mrevalence cardiac
abnormalitiesW Afap vs. efsH
vs. efsJ¥
JaaW 48 vs. 4P vs. 2M% Ep<M.MR
for Afap vs. efsJ and Afap vs.
efsHF ±
aifferences between efsH and
efsJ #
J Those with efs more
frequently had aa Elo NT.MMI
9R%Cf P.PPJ8S.9I p <M.MMNF
iuoI 2MN4 xN4] ChinaI
upperJmiddle
income
iongitudinal caseJ
control
P2R starting AoT ETP%FI
P8.2 years ENM.NF; and 9T
efsJ E8M%FI PT.8 years
ENN.MF
Cardiac
abnormalities
mrevalence cardiac normalitiesW
on AoT Eafter 48 weeksF vs.
AoT naïve vs. efsJ¥
JaaW 2P.P vs. NS.R vs. T.2%I
Ep=M.M2T for AoT naïve vs.
efsJF
Jieft ventricular systolic
dysfunctionW 9.8 vs. T.P vs. 2.N%
Ep=nsF °
Jmulmonary arterial
hypertensionW S.9 vs. 2.T vs.
T.P% Ep=nsF
Jfncreased left ventricular massW
NR.S vs. NN.N vs. R.N% Ep=nsF ~
aifferences between efsH and
efsJ #
JThose with efs more
frequently had increased left
ventricular mass Elo P.TSI
9R%Cf N.NPJN2.RPI p=M.MPNF and
aa Elo P.SR 9R%Cf N.P4J9.98
p=M.MN2F
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ptudy ErefsF CountryI income
group
ptudy design mopulation
k E% maleFI mean age
EpaF
lutcome cindings
aoI 2MNS xNR] Asia EThailandI
sietnamI fndonesiaI
fndiaI eong hongI
mhilippinesI TaiwanI
MalaysiaI gapanI
pouth horeaI
pingaporeI ChinaFI
kLA
CrossJsectional N49S on AoT ES8%FI 44.M
years EP8.RJRM.4F**
mrevalence of high E≥NM%F RJ
year risk of CsaI CeaI and Mf
JCsaW NR.R%
JCeaW NN.N%
JMfW R.S%
himI 2MNP xNS] pouth horeaI
high income
CrossJsectional
caseJcontrol
NNS efsHE9T%F and 22S
efsJ E9R%FI 4N.9 years
E8.9F
NMJyear Csa risk mrevalence of NM yearJCsa risk
in efsH vs. efsJ
J<NM% riskW TM.T vs. 8M.R%;
JNMJNR% riskW N4.T vs. NM.S%;
JNSJ2M% riskW R.2 vs. S.2%;
J>2M% riskW N.T vs. 2.T%
JEp=M.T8F
puppadungsukI 2MNP
xNT]
ThailandI
upperJmiddle
income
CrossJsectional NM9 EST%FI 4T.P years
E9.TF
eigh NMJyear
Csa risk*
mrevalence of high E≥NM%F NM
yearJCsa risk
JNN% EoamaJbdATF
bdwardsJgacksonI
2MNN xN8]
ThailandI
upperJmiddle
income
CrossJsectional T8R ERR%FI 4N.M years
ET.TF
eigh NM year
Cea risk *
mrevalence of high E≥NM%F NM
yearJCea risk
JM.8% EaWAWaF
J2.N% EoamaJbdATF
J9.9% EcopF
AbbreviationsW k=number; pa=standard deviation; unsp.=unspecified; lo=odds ratio; Cf=confidence interval; p=probability; Cea=coronary heart
disease; AoT=antiretroviral therapy; Csa=cardiovascular disease; efsHLJ=efs positiveLnegative individuals; vs.=versus; aa=diastolic dysfunction;
Mf=myocardial infarction. * >NM% risk; # findings from multivariate analysis; ^ study included patients aged >NP year; ¥ measured by twoJdimensional
transthoracic echocardiography; ± defined according to pulse wave aoppler parameters for mitral inflow; ° defined by left ventricular ejection fraction
<4R%; ~ ≥ NNM gLm2 after body surface area indexation.
P. bpTfMATbp lc CAoaflsApCriAo afpbApb ofph
Additional information on Csa risk among efsJpositive populations is provided by studies that estimate Csa risk
using various risk assessment systemsI such as the oamaJbdAT risk scoreI the cramingham risk score EcopF and the
aWAWa risk score. oisk scores of ≥NM% are commonly considered as having high risk of developing Csa in the future.
lne study investigated various Csa risk outcomes in a multiJcountry analysis and showed that high RJyear risk of
CsaI Cea and myocardial infarction was prevalent in NSI NN and S% of the treated populationI respectively xNR].
fn pouth horeaI NMJyear Csa risk was compared among efs positive and negative patients using the cop xNS].
eigh Csa risk was more common in efs positive than in efs negative individuals E29.P vs. N9.R%FI although this
difference was not significant.
rsing the oamaJbdAT risk scoreI one study estimated that NN% of the efs patients from a clinic in Bangkok had a
high NMJyear risk of Csa events xNT]. Another Thai study estimated the NMJyear risk for Coronary eeart aisease ECeaF
with each of the scoring systems and found that the prevalence of high NMJyear Cea risk was M.8%I 2.N% and 9.9% as
calculated by the aWAWaI oamaJbdAT and copI respectively xN8].
4. ofph cACTlop lc CAoaflsApCriAo afpbApb
Table 2 provides an overview of the studies on modifiable risk factors of Csa and efs.
4.N. Blood iipid mrofiles
Blood lipid profiles are generally considered abnormal when there are high levels of triglycerides E≥NRM mgLdiFI
total cholesterol ETC ≥2MM mgLdiFI lowJdensity lipoprotein cholesterol Eiai ≥NPM mgLdiF andLor low levels of eai
E<4M mgLdiF.
Abnormalities  in  one  or  more  of  these  blood  lipids  are  commonly referred to as dyslipidaemia. peveral studies
from the Asian region showed that dyslipidaemia was less prevalent in patients who were first  presented with efs
compared to their efs negative counterparts xN9I 2M]. Cholesterol levels were on average lower in efs positive patients
xN9 J 22]I whereas findings were inconsistent regarding triglyceride levels xN9 J 2N].
(Table 1) contd.....
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Treatment   with   AoT   appears   to   have   an   unfavourable   effect   on   blood   lipid   levels.   fn  MalaysiaI  
dyslipidaemia  was  reported  in  82%  of  patients  on  AoT x2P]. lther  evidence  from  the  Asian  region  indicated 
abnormal  levels  of  triglyceridesI  TCI  iai and eai in TJP9%I PJ8%I 2JNT% and N9J8S% of AoT naïve patientsI
respectively xN9 J 22I 24 J 2S]I compared  to  P9JR4%I  2SJR4%I  22J48%  and  N4JS8%  of  AoT  experienced  patientsI 
respectively  xNRI N9I 2MI 2P J 2T].
MoreoverI  a  Thai  study  showed  that  the  prevalence  of  abnormal  lipid  levels  was  even  higher  in  those  on  mfJ
containing  AoT  regimens  x28].  ptudies  from  highI  upperJmiddle  and  lowerJmiddle  income  groups  all  confirmed
significant associations between AoT use and unfavourable lipid levels xNSI N9I 2RI 2SI 29I PM].
Table 2. pummary of studies assessing the prevalence or incidence of Csa risk factors.
ptudy ErefsF CountryI income
group
ptudy design mopulation
k E% maleFI mean age EpaF
lutcomeEsF cindings
CareyI 2MNP xN9] fndiaI
lowerJmiddle
income
CrossJsectional R9 on AoT ER8%FI P9.2 years
E9.NF; SS AoT naïve EP4%FI
PP.N years ES.NF; and TR efsJ
ES9%FI PT.T years E8.TF
iipid levelsI
diabetesI
hypertensionI
obesity
mrevalence of medical risk
factorsW AoT vs. AoT naïve vs.
efsJ
JAbdominal obesityW PR.M vs.
PS.R vs. 4S.T% Ep=nsF
JeypertensionW NT.P vs. N2.N vs.
PS.M% Ep=M.MM2F
JeyperglycaemiaW P4.M vs. 2M.T
vs. PN.2% Ep=nsF
Jfnsulin resistanceW 8.2 vs. P.S
vs. P.4%Ep=nsF
Jeigh TCW PS.M vs. S.9 vs. 2M.M%
Ep=M.MMNF
Jiow eaiW R4.M vs. 8S.2 vs.
T8.4% Ep<M.MMNF
Jeigh iaiW P4.M vs. NT.2 vs.
PR.4% Ep=M.MRF
Jeigh triglyceridesW 48.M vs. NT.2
vs. 2M.M% Ep<M.MMNF
aifferences between on AoT
and AoT naïve^
JThose on AoT more frequently
had high triglycerides Elo R.2I
9R%Cf N.PJ2M.PI p=M.MN9F
JThose on AoT less frequently
had hypertension Elo M.2I
9R%Cf M.MPJM.9I p=M.MPTFI and
high triglycerides Elo 8.MI
9R%Cf N.9JP2.2I p=M.MMPF
halyanasundaramI
2MN2 x2M]
fndiaI
lowerJmiddle
income
CrossJsectional N4R on AoT E4T%F; N4S AoT
naïve ERN%F; and T2 efsJ
ER4%FI PP.9 years ET.2F
iipid levels mrevalence of medical risk
factorsW AoT vs. AoT naïve vs.
efsJ
Jeigh TCW P8.S vs. 4.N vs.
NS.T%I p<M.MR;
Jiow eaiW 24.8 vs. TP.P vs.
4M.P%I p<M.MR;
Jeigh iaiW PN.M vs. S.2 vs.
NR.P%I p<M.MR;
Jeigh triglyceridesW 42.N vs. S.8
vs. 2M.8%I p<M.MR
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ptudy ErefsF CountryI income
group
ptudy design mopulation
k E% maleFI mean age EpaF
lutcomeEsF cindings
phenI 2MNR x2N] ChinaI
upperJmiddle
income
CrossJsectional NRN8 AoT naïve ETR%FI P8
years Eunsp.F*; and P4T efsJ
EPS%FI PT years Eunsp.F*
iipid levels mrevalence of medical risk
factorsW efsH vs. efsJ
Jeigh TCW 8.4 vs. 28.2%
Ep<M.MMNF
Jiow eaiW R9.S vs. NN.2%
Ep<M.MMNF
Jeigh iaiW 8.R vs. S2.S%
Ep<M.MMNF
Jeigh triglyceridesW PP.9 vs.
NT.M% Ep<M.MMNF
aifferences between efsH and
efsJ^
JThose with efs less frequently
had high TC Elo M.29I 9R%Cf
M.2NJM.4NI p<M.MMNF and high
iai Elo M.MSI 9R%Cf
M.M4JM.M9I p<M.MMNF
JThose with efs more
frequently had high triglycerides
Elo 2.TT 9R%Cf 2.M4JP.TR
p<M.MMNFI and low eai Elo
8.R8 9R%Cf R.2TJNP.9S
p<M.MMNF
tangI 2MNS x22] ChinaI
upperJmiddle
income
Case Control P2M men who have sex with
men of whom NMM efsJ
ENMM%FI P2.2 years E9.MF; NNM
AoT naïve acute efs AoT
ENMM%.FI PN.R years E8.SF;
NNM AoT naïve chronic efs
infection ENMM%.FI PP.8 years
ES.2F
iipid levelsI
hypertensionI
blood glucose
levelsI tobacco
use
mrevalence of medical risk
factorsW efsJ vs. acute efs vs.
chronic efs
Jeigh TCW 2N.M vs. S.4 vs. 2.T%
Ep<M.MR efsJ vs. acute and vs.
chronicF
Jiow eaiW NT.M vs. PP.S vs.
4M.M% Ep<M.MR efsJ vs. acute
and vs. chronicF ±
Jeigh iaiW NS.M vs. N.8 vs.
N.8% Ep<M.MR efsJ vs. acute
and vs. chronicF ∞
Jeigh triglyceridesW 2P.M vs. NR.R
vs. 2M% Ep=nsF
JayslipidemiaW 44.M vs. 4S.4 vs.
4T.P% Ep=nsF
JeypertensionW NT.M vs. 9.N vs.
NT.P% Ep=nsF
mrevalence of behavioural risk
factorsW efsJ vs. acute efs vs.
chronic efs
Jbver pmokingW P8.M vs. 2S.4 vs.
PP.S% Ep=nsF
aifferences between efsJ and
acute efs
JThose with acute efs had
lower triglyceridesI TCI eai
and iai Ep<M.MRF
aifferences between efsJ and
chronic efs
JThose with chronic efs had
lower triglyceridesI TCI eai
and iai Ep<M.MRF
JThose with chronic efs had
higher blood glucose levels
Ep<M.MRF
eejaziI 2MNP x2P] MalaysiaI
upperJmiddle
income
CrossJsectional 2TP9 on AoT E8N%FI 4P.N
years E9.9F
iipid levelsI
diabetes
mrevalence medical risk factors
Jeigh TCW R4.2%
Jiow eaiW 28.T%
Jeigh iaiW PR.N%
Jeigh triglyceridesW R9.N%
JayslipidaemiaW 82.P%
JeyperglycaemiaW P8.2%
Jaiabetes mellitusW N2.9%
(Table ?) contd.....
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ptudy ErefsF CountryI income
group
ptudy design mopulation
k E% maleFI mean age EpaF
lutcomeEsF cindings
aoI 2MNS xNR] Asia EThailandI
sietnamI
fndonesiaI fndiaI
eong hongI
mhilippinesI
TaiwanI MalaysiaI
gapanI pouth
horeaI pingaporeI
China
CrossJsectional 42T4 efs ETN%FI 4M.T
EP4.RJ4T.SF***
aata available medical risk
factorsW
N49S on AoT ES8%FI 44.M
years EP8.RJRM.4F**
iipid levelsI
diabetesI
hypertensionI
tobacco use
mrevalence medical risk factors
JeypertensionW 2M.P%
Jaiabetes mellitusW 8.P%
Jeigh TCW 4R.9%~
Jiow eaiW 2N.R%
Jeigh triglyceridesW P9.M%€
mrevalence behavioural risk
factors
JCurrent smokingW 2P.2%
Jcormer smokingW 2M.P%
aifferences between countries
JCompared the ThailandI the
prevalence of smoking was
significantly lower in fndia and
the mhilippines and higher in
sietnamI fndonesiaI eong
hongI TaiwanI MalaysiaI gapanI
pouth horea and pingapore
Ep<M.MMNF
BajajI 2MNP x24] fndiaI
lowerJmiddle
income
CrossJsectional TM efsH ETN%FI age unsp.W
4T on AoT;
2P AoT naïve
Metabolic
syndrome and its
components
mrevalence of medical risk
factorsW AoT vs. AoT naïve
JMetabolic syndromeW N9.N vs.
2N.T% Ep=nsF
Jiow eaiW RR.P vs. P4.8%
Ep=nsF
Jeigh triglyceridesW 44.T vs.
P9.N% Ep=nsF
JeyperglycaemiaW 2T.T vs.
PM.4% Ep=nsF ¥
JeypertensionW N4.9 vs. 8.T%
Ep=nsF
gantarapakdeI 2MN4
x2R]
ThailandI
upperJmiddle
income
CrossJsectional 4NM on AoT ERN%FI P9 years
EP4J44F; and NTM AoT naïve
EPR%FI P4 yearsE29J4MF #
Metabolic
syndrome and its
components
mrevalence of medical risk
factorsW AoT vs. AoT naïve
JMetabolic syndromeW 24.9 vs.
NR.9 Ep=M.MN8F
JeypertensionW 2T.8 vs. 22.4
Ep=nsF
Jiow eaiW 4M.M vs. TM.S
Ep<M.MRF
Jeigh triglyceridesW 4T.8 vs. 2R.P
Ep<M.MRF
JeyperglycaemiaW 24.4 vs. NN.T
Ep<M.MRF
JAbdominal obesityW 29.M vs.
P2.9% Ep=nsF
fndumatiI 2MN4 x2S] fndiaI
lowerJmiddle
income
Cross sectional NMM AoT naïve EST%FI PR.8
years E9.NF; NMM on AoT
ESM%FI PS.M years E9.MF
iipid levels mrevalence of medical risk
factorsW AoT vs. AoT naïve
Jeigh TCW 49 vs. 8% E<M.MMMNF
Jiow eaiW S8 vs. 8N%
Ep=M.MPSSF
Jeigh iaiW 48 vs. R%
Ep<M.MMMNF
Jeigh triglyceridesW 48 vs. 2T%
Ep=M.MM24F
aifferences between on AoT
and AoT naïve
JThose on AoT had higher TC
Em<M.MMMNFI iai Em<M.MMMNFI
triglycerides Ep=M.MM4RF
hiertiburanakulI 2MN2
x2T]
ThailandI
upperJmiddle
income
CrossJsectional N29 on AoT ERM%FI 4S.2
years E9.PF
iipid levelsI
diabetes
mrevalence of medical risk
factors
JayslipidaemiaW R8.9%
Jeigh TCW 2R.S% ~
Jiow eaiW N4.M% ±
Jeigh iaiW 2N.T% °
Jeigh triglyceridesW RM.4%
JaiabetesW R.4%
(Table ?) contd.....
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ptudy ErefsF CountryI income
group
ptudy design mopulation
k E% maleFI mean age EpaF
lutcomeEsF cindings
himI 2MNP xNS] pouth horeaI
high income
CrossJsectional
caseJcontrol
NNS on AoT E9T%F; and 22S
efsJ E9R%FI 4N.9 years E8.9F
iipid levelsI
blood pressure
aifferences after AoT initiationF
JAfter S months AoT
individuals had increased TC
Ep<M.MMNF; eai Ep<M.MMNF;
iai Ep=M.MMTF; and
triglycerides Ep<M.MMNF
aifferences between on AoT
and efsJ
JThose on AoT had lower TC
Ep=M.M2PFI eai Ep=M.MN9FI
iai Ep<M.MMNFI and BMf
Ep<M.MMNF
J Those on AoT had higher
triglycerides Ep<M.MMNFI systolic
Bm Ep<M.MMNFI and diastolic Bm
Ep<M.MMNF
eomsanitI 2MMT x28] ThailandI
upperJmiddle
income
CrossJsectional N2S naïve E28%FI PP.S years
ES.RF; SN on mfJcontaining
AoT ERT%FI P8.9 years ES.TF;
SM on other AoT E4R%FI PT.M
years E8.4F
iipid levelsI
diabetesI
abdominal obesity
mrevalence of medical risk
factorsW AoT naïve vs. mf
containing AoT vs. nonJmf AoT
Jeigh TCW N8.P vs. TR.4 vs.
R8.P% Ep<M.MMNF
Jiow eaiW 42.9 vs. PN.2 vs.
2M% Ep=M.MMTF
Jeigh iaiW NR.N vs. R9.N vs.
4N.T% Ep<M.MMNF
Jeigh triglyceridesW 8.2 vs. TR.4
vs. 48.P% Ep<M.MMNF
JaiabetesW M vs.. S.S vs. N.T%
Ep=M.M4F
aifferences between AoT naiive
and those on mf containing AoT
JThose in mfJcontaining AoT
had higher waist circumference
Ep=M.MM4F and waistJtoJhip ratio
Ep<M.MMNF
aifferences between AoT naiive
and those on nonJmf containing
AoT
JThose in nonJmfJcontaining
AoT had higher waist
circumference Ep=M.MM2F and
waistJtoJhip ratio Ep<M.MMNF
duptaI 2MNN x29] fndiaI
lowerJmiddle
income
iongitudinal S8 starting AoT E84%FI PR.9
years E9.4F
Metabolic
syndrome and its
components
fncidence rate of medical risk
factors after S months AoT
JMetabolic syndromeW2R.M%
JeypertensionW NM.P%
Jfmpaired fasting glucoseW 4.2%
Jaiabetes mellitusW 2.N%
aifferences after AoT initiation
JAfter S months AoTI
individuals had increased
systolic BmI diastolic BmI BMfI
skinfold thicknessI blood
glucoseI TCI eai and iai
madmapriyadarsiniI
2MNN xPM]
fndiaI
lowerJmiddle
income
iongitudinal NS8 TB coJinfected ET9%FI on
bcsW PR years ES.9F; on
ksmW PT years ET.TF
iipid levelsI
glucose levels
fncidence rate of medical risk
factors after N2 months AoT
Jeigh TCW 2S%
Jiow eaiW 2P%
Jeigh iaiW M%
Jeigh triglyceridesW 2M%
Jblevated blood glucose levelsW
NN% ¥
aifferences after AoT initiation
JAfter S and N2 months of AoTI
individuals had increased
cholesterolI eai and iai
Ep<M.MMNF
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ptudy ErefsF CountryI income
group
ptudy design mopulation
k E% maleFI mean age EpaF
lutcomeEsF cindings
fdicullaI 2MNN xPN] fndiaI
lowerJmiddle
income
CrossJsectional PM on AoT ETT%FI 4N.S years
ENM.9F; and PM AoT naïve
ETM%FI 4M.S years E9.RF
Metabolic
syndrome and its
components
mrevalence of medical risk
factorsW AoT vs. AoT naïve
JMetabolic syndromeW 4P.P vs.
NM% Ep=M.M28F;
Jfnsulin resistanceW S2.R vs.
PT.R% Ep=nsF
phenI 2MNP xP2] ChinaI
upperJmiddle
income
CrossJsectional 2MMS AoT naïve ETS%F 4M
years EN8J8SF*
aiabetes mrevalence of medical risk
factors
Jaiabetes mellitusW NM.R2%;
Jblevated blood glucose levelsW
N9.9T% ¥
ZhangI 2MNR xPP] ChinaI
upperJmiddle
income
iongitudinal 4NR starting AoT ET4%FI 24
years E2T.4NF #
aiabetes fncidence medical risk factors
Jaiabetes mellitusW 2.S2 per NMM
py
Jfmpaired fasting glucoseW PR.S4
per NMM py
oiyatenI 2MNR xP4] ThailandI
upperJmiddle
income
iongitudinal NR94 on AoT E24%FI P2.R
years E28.2JPT.TF #
aiabetes fncidence of medical risk factors
Jaiabetes mellitusW R.M per NMMM
py E9R%Cf P.8JS.SF
ioI 2MM9 xPR] TaiwanI
high income
oetrospective
caseJcontrol
824 >9R% on AoT E92%FI P4
years E28J4MF**I of whom RM
newJonset aM cases; NMM
matched controls >9R% on
AoT E8S%FI 48 years
E4PJRSF** without aM
aiabetes fncidence of diabetesJ
JNP.N cases per NMMM personJ
years
privanich 2MNM xPS] ThailandI
rpperJmiddle
income
CrossJsectional N49 nonJdiabetics 92% on
AoT ESR%FI 42.2 years ENM.MF
dlucose levels mrevalence of medical risk
factorsJ
Jfmpaired fasting glucoseW
2T.R%
eejaziI 2MN4 xPT] MalaysiaI
upperJmiddle
income
CrossJsectional P4M on AoTW N8R
normotensive ET2%FI 4M.2
years ET.SF; and NRR
hypertensive E8T%FI 4P.9
years ENM.2F
eypertension mrevalence medical risk factors
JeypertensionW 4R.S%
tuI 2MN2 xP8] TaiwanI
high income
CrossJsectional 8MP on AoT E9R%FI
metabolic syndromeW 44.R
years E9.TF; and no metabolic
syndromeW PS.8 years ENM.SF
Metabolic
syndrome
mrevalence of medical risk
factor
JMetabolic syndromeW 2S.2%
iuoI 2MN4 xP9] ChinaI
upperJmiddle
income
CrossJsectional 4RR on AoTLAoT naïve
ESS%FI P8.N years E8.8F
Tobacco use mrevalence of behavioural risk
factors
JpmokingW SN.T%
kguyenI 2MNR x4M] sietnamI
lowerJmiddle
income
CrossJsectional NNPP on AoT ER9%FI PR.R
years ES.9F
Tobacco use mrevalence of behavioural risk
factors
JCurrent smokingW PS.N%
Jmast smokingW 9.R%
lkaI 2MNP x4N] gapanI
high income
CrossJsectional NMM on AoTLAoT naïve
ENMM%FI 42.N years EN2.TF
Tobacco use mrevalence behavioural risk
factors
JpmokingW 4M%
iallI 2MNS x42] fndiaI
lowerJmiddle
income
CrossJsectional R42 efsH ERR%FI N982M8
efsJ EPT%FI age unsp.
Tobacco use mrevalence behavioural risk
factorsW efsH vs. efsJ
JTobacco use Eincl. smokingF in
menW S8 vs. R8% Ep<M.MMRF
JTobacco use Eincl. smokingF in
womenW N2 vs. NN% Ep=not
testedF
aifferences between efsH and
efsJ
JThose with efs more
frequently were a smoker Elo
N.48I 9R%Cf N.MRJ2.NI p<M.MRF
AbbreviationsW k=number; pa=standard deviation; AoT=antiretroviral therapy; TB=tuberculosis; bcs=efavirenz; ksm=nevirapine; efsHLJ=efs
positiveLnegative individuals; unsp.=unspecified; lo=odds ratio; Cf=confidence interval; p=probability; ns=not significant; vs.=versus; TC=total
cholesterol; eai=high density lipoproteinJcholesterol level; iai=low density lipoproteinJcholesterol level; Bm=blood pressure; py=person year. *
Age in median ErangeF; # age in median EfnoF; ^ findings from multivariate analysis;¥based on older definition of hyperglycaemiaI >NNM mgLdi; ±
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eai <PR mgLdi; ° iai>NSM mgLdi; ~ TC >24M mgLdi; ∞iai≥NPR mgLdi; € Triglycerides>2MM mgLdi.
4.2. aiabetes and Abnormal Blood dlucose ievels
fnformation regarding glucose levels has frequently been described in studies from fndia.  fn a study comparing
glucose levels among AoT experienced patientsI AoT naïve patients and efs negative individualsI hyperglycaemia
Efasting plasma glucose ≥NMM mgLdiF was observed in P4I 2N and PN% of the participantsI respectively xN9]. fn contrastI
in a study evaluating AoT naïve and experienced patientsI no significant difference in hyperglycaemia prevalence was
found between the two patient groups x24].  fnterestinglyI  one study showed a significant increase in blood glucose
levels  in  efs patients  after  they started  AoT x29].  fn  factI  after  six  months  of  AoTI  4.2% of  patients  were  newly
diagnosed with impaired fasting glucose Efasting plasma glucose NMMJN2R mgLdiFI while an additional 2.N% of patients
developed diabetes Efasting plasma glucose >N2R mgLdiF. A cohort study evaluated blood glucose levels in tuberculosis
coJinfected efs patients xPM]. Twelve months after AoT initiationI elevated blood glucose levels E>NNM mgLdiF had
developed in NN% of patients. eoweverI compared to before AoT initiation there was no significant difference in the
prevalence of abnormal blood glucose levelsI since abnormalities did not persist in all baseline cases xPM]. Two studies
evaluated insulin resistance and found it more frequent in those on AoT than in those who had not yet started treatmentI
albeit not significantly xN9I PN].
Additional information on diabetes and blood glucose levels was available from other Asian countries. fn ChinaI
blood glucose levels were higher in efs positive than efs negative men x22]. curthermoreI 2M% of Chinese AoTJ
naïve patients had elevated blood glucose levelsI of whom NN% met the criteria for diabetes xP2]. lther findings from
China showed that diabetes and impaired fasting glucose developed relatively frequently in patients after they initiated
AoT Eincidence of 2.S2 and PR.S4 per NMM personJyearsI respectivelyF xPP]. pubstantiallyI lower diabetes incidence rates
were found in  AoT experienced patients  in  Thailand ER.M  per  NMMM personJyearsF  xP4]  and in  highJincome country
Taiwan ENP.N per NMMM personJyearsF xPR]. fn ThailandI the diabetes prevalence was R.4% in a study population NM years
after efs diagnosis x2T] and Edepending on the type of regimenF ranged from N.TJS.S% in another AoT treated study
population x28]I while impaired fasting glucose was seen in 28% of a nonJdiabetic population of whom the majority
was on AoT xPS]. fn  Malaysian  patients  on  AoTI  the  prevalence  of  diabetes  and  hyperglycaemia  was  NP  and
P8%I respectively x2P].  A  lower  prevalence  of  hyperglycaemia  was  reported  among  efs  infected  patients 
assessed  in  ThailandI  with  the  proportion  in  AoT  experienced  patients  being  higher  than  in  AoT  naïve 
patients E24 vs. N2%I p <M.MRF x2R]. iastlyI an analysis on the wider Asian region showed a mean diabetes prevalence of
8.P% xNR].
4.P. eypertension
There is inconclusive evidence from the Asian region regarding hypertension and differences across efs or AoT
status. cor exampleI no significant differences were found between efs negative and positive men in China x22]. fn
additionI AoT naïve patients in fndia had a relatively low prevalence of hypertension EN2%F compared to efs negative
individuals EPS%F and AoT experienced patients ENT%I p=M.MM2F xN9]. lther findings from fndia indicate no difference
with regard to hypertension between AoT naïve and experienced patients x24]I while a cohort study showed an increase
in average systolic and diastolic blood pressure after S months on AoTI with NM% of efs patients having developed
hypertension x29]. A Thai studyI howeverI reported no significant difference in the prevalence of hypertension between
AoT naïve and AoT experienced patients E22 vs. 28%F x2R]. fn MalaysiaI hypertension was reported in almost half of
efs patients on AoT xPT]. cinallyI a multiJcountry study showed that around 2M% of AoT experienced individuals had
hypertension xNR].
4.4. Metabolic pyndrome
Based  on  studies  from  fndiaI  Thailand  and  TaiwanI  the  prevalence  of  metabolic  syndromeI  a  set  of  clinical
parameters associated with the development of heart disease and other health problems such as diabetesI varied from
N9J4P% for  efs patients  who  were  on  AoT x24I  2RI  PNI  P8].  cindings  suggest  that  AoT has  a  negative  effect  on
metabolic functioning. This is illustrated by two studies that reported a significantly higher prevalence of metabolic
syndrome in AoT experienced than AoT naïve patients x2RI PN] and by a longitudinal study that described new onset
metabolic syndrome in 2R% of study participants S months after AoT initiation x29].
4.R. Abdominal lbesity
Abdominal  obesity  is  a  wellJknown  contributor  to  hypertensionI  diabetes  and  metabolic  syndrome.  fn  AoT
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experienced efs patients in Thailand abdominal obesity was prevalent in P9% x2R]I which is similar to findings from
an  fndian  study  xN9].  fn  both  studiesI  the  prevalence  in  patients  on  AoT  was  comparable  to  AoT  naïve  peers.
fnterestinglyI findings from an fndian cohort study suggest that AoT might eventually negatively affect healthy body
massI with study participants having increased BMf and skinfold thickness after S months of AoT x29]. iikewiseI waist
circumference  and  waistJtoJhip  ratio  were  significantly  higher  in AoT  experienced  compared  to  AoT  naïve 
individuals x28].
4.S. Tobacco rse
Across the Asian regionI the proportion of current smokers ranged from 2PJS2% xNRI 22I P9 J 4N] and that of former
smoker from NMJ2M% xNRI 4M]. lne study specifically compared smoking among Asian populations on AoT and found
that compared to ThailandI the prevalence of smoking was lower in fndia and the mhilippinesI while it was higher in
sietnamI  fndonesiaI  eong  hongI  TaiwanI  MalaysiaI  gapanI  pouth  horea  and  pingapore  xNR].  fn  other  studiesI  the
prevalence of current smoking was notably higher in men x4MI 42]. curthermoreI when comparing across efs statusI in
fndia those with efs were more likely to smoke Ep <M.MRF x42]I whereas in Chinese men who had sex with men there
were no significant differences between those with or without efs x22].
R. MAkAdbMbkT lc Csa fk efs mlmriATflkp
pince efs populations are at increased Csa riskI screening approaches designed for the general population may
underestimate individual Csa risk. eenceI it is recommended that clinicians consider using efs specific risk scoring
systems or  take  into  account  that  efs infection  is  an  additional  risk  factor  and  provide  Csa preventive  measures
accordingly. As shown by a metaJanalysis of observational studiesI increased Csa risk might be attributable to specific
antiretroviral drugsI such as abacavirI indinavir and lopinavir x4P]. kewer generations of drugs could diminish Csa
risk  x44]I  howeverI  these  drugs  might  not  be  available  in  lowJresource  settings.  ft  is  of  particular  importance  that
clinicians carefully select AoT regimensI thereby limiting adverse events that increase Csa risk. MoreoverI health
systems should plan for and ensure access to the most appropriate AoT.
dloballyI there are limited specific guidance and recommendations on the joint management and prevention of Csa
in  efs  patients.  eoweverI  guidelines  for  efs  treatment  do  offer  some  support  on  the  management  of  Csa  and
associated risks in efsJinfected patients. cor exampleI in limited resource settingsI tel efs treatment guidelines
recommend the  use  of  statins  for  people  with  a  NMJyear  Csa risk  exceeding  PM%I  and  caution  the  use  of  boosted
protease inhibitors with lovastatin and simvastatin as drug interactions may lead to increased risk of developing serious
adverse  effects  x4R].  Although  national  efs  treatment  guidelines  from  the  Asian  region  generally  provide
recommendations with regard to screening and monitoring of patients prior to AoT initiation and afterwards ETable PFI
the current routinely collected patient data in some countries might be insufficient to estimate individual Csa risk and
provide preventive treatment accordingly. curthermoreI not all guidelines provide information with regard to possible
interactions between AoT and other drugs Ei.e. antiplatelet or statinF that might prevent or treat Csa x4S J 48].
Table P. CsaJrelated recommendations in national efs guidelines from the Asian region.
CountryI year ErefsF pcreening Monitoring iisting drug
interactions
horeaI 2MNP x4S] Medical history
iipid profile
casting blood sugar
iipid profile
casting blood sugar
ko
mhilippinesI 2MM9 x4T] iipid profile
casting blood glucose
iipid profile
casting blood glucose
ko
ThailandI 2MN4 x48] iipid profile
casting blood glucose
iipid profile
casting blood glucose
ko
MalaysiaI 2MNN x49] Medical history
iipid profile
casting blood glucose
iipid profile
casting blood glucose
ves
fndiaI 2MNP xRM] Medical history
iipid profile
casting blood glucose
iipid profile
casting blood glucose
ves
sietnamI 2MM9 xRN] Medical history
iipid profile
casting blood glucose
iipid profile
casting blood glucose
ves
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CountryI year ErefsF pcreening Monitoring iisting drug
interactions
CambodiaI 2MN2 xR2] Medical history
iipid profile
casting blood glucose
iipid profile ves
MyanmarI 2MNN xRP] kot specified iipid profile
casting blood glucose
ves
eong hongI 2MNP xR4] NMJyear Csa risk
Medical history
camily history of Csa
iipid profile
casting blood glucose
NMJyear Csa risk
iipid profile
casting blood glucose
ves
bnglish versions of guidelines were not available online for gapanI fndonesiaI and Taiwan
ClkCirpflk Aka crTrob afobCTflkp
The  limited  findings  available  from  this  review  suggest  that  efsJpositive  populations  in  Asia  are  prone  to
developing Csa. thile compared to efsJnegative individualsI blood lipid levels tend to be lower in newly diagnosed
efs patientsI  an unfavourable rise in lipid levels  is  common after  AoT initiation.  curthermoreI  compared to efsJ
negative individualsI  smoking is  highly prevalent  in  those with efsI  especially  in  men.  AdditionallyI  a  substantial
proportion of efs populations appear to be affected by cardiac abnormalities and other Csa risk factors such as high
glucose levelsI metabolic syndrome and abdominal obesity. Caution is warranted when interpreting these findings since
there may be important sociodemographic differences between Asian countriesI such as those related to country income
level. curthermoreI comparing the findings between countries is difficult due to differences across studiesI such as study
definitionsI measures to define CsaI study populations Ee.g. size and selection criteriaF and study limitationsI indicating
that more research is warranted on Csa and Csa risk factors in Asia. konethelessI these data suggest that as the efs
population agesI Csa will become an increasing source of morbidity and mortality in the Asian region.
bnglish  versions  of  national  guidelines  for  efs  treatment  include  limited  recommendations  on  Csa  risk
assessment and management. Although guidelines published in national language may be more specificI it is unclear to
what extent these are implemented. Clinicians caring for efsJinfected patients should have guidance on assessing and
managing  Csa  and  associated  risksI  and  optimal  treatment  options  and  drugJdrug  interactions  readily  available.
curthermoreI in the context of the strained health systems and competing health priorities of lowJtoJmiddle income
countriesI it might be challenging to ensure access to Csa services for efs patients who are at increased Csa riskI
especially for key affected populations. To overcome these issuesI there is an urgent need for guidelines that integrate
Csa risk prevention and management into efs care.
lptimal  prevention  and  management  are  vital  in  dealing  with  the  rising  burden  of  Csa  in  efsJpositive
populations. This review illustrates that there is limited research on Csa in efsJpositive populations in the Asian
region. fn particularI there is a need for more largeJscale studies which compare absolute Csa events with estimated
Csa  risk  in  efs  positive  and  negative  populations.  fn  additionI  future  research  should  assess  the  level  of
implementation of guidelines regarding Csa risk assessment and management. iastlyI further work is warranted to
explore effective Csa risk screening approaches that are feasible in the Asian regionI where resources may be limited.
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